News
today announced the initiation of a Phase 2b dose-ranging trial for its CGB-500 product. This topical JAK inhibitor ointment, developed using CAGE Bio's proprietary ionic liquid technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback